An Open Label N of 1 Study to Evaluate the Study and Efficacy of Long-Term Treatment With Ivacaftor in Combination With Ataluren (PTC124) in Subjects With Nonsense Mutation Cystic Fibrosis
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Ataluren (Primary) ; Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
- 24 Aug 2017 New trial record